NO20050398L - Nye adenosinanaloger og deres anvendelse som farmasoytiske midler - Google Patents

Nye adenosinanaloger og deres anvendelse som farmasoytiske midler

Info

Publication number
NO20050398L
NO20050398L NO20050398A NO20050398A NO20050398L NO 20050398 L NO20050398 L NO 20050398L NO 20050398 A NO20050398 A NO 20050398A NO 20050398 A NO20050398 A NO 20050398A NO 20050398 L NO20050398 L NO 20050398L
Authority
NO
Norway
Prior art keywords
pharmaceutical agents
adenosine analogues
new adenosine
compounds
new
Prior art date
Application number
NO20050398A
Other languages
English (en)
Inventor
Andreas Herling
Franz Hock
Antony Bigot
Michael R Myers
Siegfried Stengelin
Gerhard Jaehne
Guenter Mueller
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20050398L publication Critical patent/NO20050398L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med generell formel (I), hvoii R*, A, B, Q, T, W og X har betydningene gitt i beskrivelsen. Disse forbindelsene er anvendelige for fremstilling av et medikament for behandling av insulim-esisens, type 2 diabetes, meta- bolittisk syndrom, lipidforstyrrelser eller kardiovaskulær sykdom, eller for å tilveie- bringe en anti-lipolyttisk effekt.
NO20050398A 2002-06-27 2005-01-25 Nye adenosinanaloger og deres anvendelse som farmasoytiske midler NO20050398L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02014324A EP1375508A1 (en) 2002-06-27 2002-06-27 N6-substituted adenosine analogues and their use as pharmaceutical agents
PCT/EP2003/006749 WO2004003002A1 (en) 2002-06-27 2003-06-26 Novel adenosine analogues and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
NO20050398L true NO20050398L (no) 2005-01-25

Family

ID=29716849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050398A NO20050398L (no) 2002-06-27 2005-01-25 Nye adenosinanaloger og deres anvendelse som farmasoytiske midler

Country Status (19)

Country Link
EP (2) EP1375508A1 (no)
JP (1) JP2006501178A (no)
KR (1) KR20050014888A (no)
CN (1) CN1671728A (no)
AR (1) AR039697A1 (no)
AU (1) AU2003280141A1 (no)
BR (1) BR0312428A (no)
CA (1) CA2490253A1 (no)
HR (1) HRP20041209A2 (no)
IL (1) IL165934A0 (no)
MA (1) MA27465A1 (no)
MX (1) MXPA04012815A (no)
NO (1) NO20050398L (no)
PE (1) PE20040584A1 (no)
PL (1) PL375197A1 (no)
RU (1) RU2005101872A (no)
TW (1) TW200500376A (no)
WO (1) WO2004003002A1 (no)
ZA (1) ZA200410062B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006293618B9 (en) 2005-09-21 2009-10-29 Pfizer Limited Carboxamide derivatives as muscarinic receptor antagonists
JP2007153789A (ja) * 2005-12-05 2007-06-21 Mitsui Chemicals Inc 光学活性３−アミノピロリジン誘導体の製造方法
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN119039201A (zh) * 2024-07-19 2024-11-29 苏州汉德创宏生化科技有限公司 一种(s)-1-叔丁氧羰基-3-氨基吡咯烷的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545645A1 (de) * 1965-12-06 1969-08-21 Boehringer Mannheim Gmbh Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
WO1998052611A1 (en) * 1997-05-23 1998-11-26 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
PE20040584A1 (es) 2004-11-03
TW200500376A (en) 2005-01-01
MA27465A1 (fr) 2005-08-01
HRP20041209A2 (en) 2005-08-31
JP2006501178A (ja) 2006-01-12
WO2004003002A1 (en) 2004-01-08
AR039697A1 (es) 2005-03-09
MXPA04012815A (es) 2005-02-24
ZA200410062B (en) 2008-08-27
BR0312428A (pt) 2005-04-26
EP1375508A1 (en) 2004-01-02
EP1527083A1 (en) 2005-05-04
RU2005101872A (ru) 2005-08-10
AU2003280141A1 (en) 2004-01-19
IL165934A0 (en) 2006-01-15
CA2490253A1 (en) 2004-01-08
PL375197A1 (en) 2005-11-28
KR20050014888A (ko) 2005-02-07
CN1671728A (zh) 2005-09-21

Similar Documents

Publication Publication Date Title
NO20074872L (no) Pyrazoler
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
CY1108900T1 (el) Πολυθειωμενα γλυκοζιδια και αλατα αυτων
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
SE0102300D0 (sv) Compounds
WO2008042688A3 (en) Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
NO20050828L (no) lndol-3-svovelderivater
ZA200802454B (en) Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
NO20060908L (no) Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20065904L (no) Terapeutiske forbindelser
NO20054868L (no) CaSr antagonist
NO20054876L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
NO20070089L (no) DPP-IV inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application